India-made Covaxin's recently published result on efficacy will help the vaccine in getting World Health Organisation’s (WHO) emergency approval, the chairperson of National Technical Advisory Group on Immunisation in India (NTAGI), Dr NK Arora said.

“This will help to get the vaccine WHO emergency use listing,” Arora told news agency ANI.

The NTAGI chairman also said the approval from the UN health body will bring visibility to India since Covaxin is indigenously developed.

Hyderabad-based biotechnology company Bharat Biotech has claimed its anti-COVID-19 vaccine, Covaxin, is 77.8% effective against the deadly virus.

Bharat Biotech made the claim in phase three clinical trial data of the vaccine.

The company has further claimed Covaxin is 93.4% effective against severe symptomatic COVID-19 cases, 63.6% against asymptomatic COVID-19 cases and 65.2% against the Delta variant.

“Efficacy analysis demonstrates Covaxin to be 77.8% effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4% effective against severe symptomatic Covid-19,” the manufacturer said in a paper published in open access journal medRxiv.

"We are working closely with the World Health Organisation for inclusion of Covaxin in its Emergency Use Listing. Approval from WHO is not expected to be a long drawn process as the cell line and majority of our facilities have already been audited and approved by WHO for our other vaccines in the past," Ella tweeted.(SAM)